1851-P: Bromocriptine (B) plus Curcumin (C) Interact to Reduce Advanced Fibrosis in a Mouse Methionine-Choline Deficient (MCD) Diet Model of Nonalcoholic Steatohepatitis (NASH)
NASH is characterized by severe hepatic fibrosis that potentiates cirrhosis and hepatocellular carcinoma. The MCD diet also potentiates severe liver fibrosis by reducing lipid secretion and antioxidant defenses, and adversely altering the gut microbiome to promote liver inflammation and damage. B, a...
Saved in:
Published in | Diabetes (New York, N.Y.) Vol. 68; no. Supplement_1 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
New York
American Diabetes Association
01.06.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | NASH is characterized by severe hepatic fibrosis that potentiates cirrhosis and hepatocellular carcinoma. The MCD diet also potentiates severe liver fibrosis by reducing lipid secretion and antioxidant defenses, and adversely altering the gut microbiome to promote liver inflammation and damage. B, a dopamine D2 receptor agonist reduces adipose lipolysis and hepatic lipogenesis and inflammation. C improves a gut microbiome adverse to liver. C is also known to augment brain dopaminergic activity. We therefore investigated if B and C combination therapy that engages different pathological targets of NASH may provide an additive/synergistic benefit against MCD diet induced liver fibrosis. C57B6 mice were fed an MCD diet for 8 weeks to induce NASH with fibrosis then randomized to 4 treatment groups: Vehicle, B (10mg/kg), C (100mg/kg), and combination of B and C (BC) daily for 4 weeks while maintained on the diet. A group of mice on normal diet were used as normal reference control. BC therapy led to significant reductions of serum ALT (85%), serum AST (33.4%), liver steatosis (65.4%), inflammation (86.7%), ballooning degeneration (60%), and NAFLD activity score (86.4%), as well as gene expression markers each of fibrosis (αSMA, TGFβ, COL1A, TXNIP) by 88-92%, inflammation (TNFa, IL1β, MCP1, iNOS) by 91-97%, ER stress (DDIT3, ATF, sXBP1, HSPA5) by 45-93%, steatosis (ACC1, PLIN2) by 31-97%, and fatty acid oxidation (PPARα, PGC1α, CPT1, UCP1) by 65-86, and reduced the percent fibrosis area by 92.7% relative to vehicle (and resultantly similar to normal diet mice) (all above: P<0.05) and by amounts greater than B or C alone or additively. This study demonstrates the positive interactive effects of bromocriptine and curcumin on advanced liver fibrosis in an MCD diet model of NASH.
Disclosure
T. Tsai: Employee; Self; VeroScience LLC. A. Cincotta: Employee; Self; VeroScience LLC. |
---|---|
AbstractList | NASH is characterized by severe hepatic fibrosis that potentiates cirrhosis and hepatocellular carcinoma. The MCD diet also potentiates severe liver fibrosis by reducing lipid secretion and antioxidant defenses, and adversely altering the gut microbiome to promote liver inflammation and damage. B, a dopamine D2 receptor agonist reduces adipose lipolysis and hepatic lipogenesis and inflammation. C improves a gut microbiome adverse to liver. C is also known to augment brain dopaminergic activity. We therefore investigated if B and C combination therapy that engages different pathological targets of NASH may provide an additive/synergistic benefit against MCD diet induced liver fibrosis. C57B6 mice were fed an MCD diet for 8 weeks to induce NASH with fibrosis then randomized to 4 treatment groups: Vehicle, B (10mg/kg), C (100mg/kg), and combination of B and C (BC) daily for 4 weeks while maintained on the diet. A group of mice on normal diet were used as normal reference control. BC therapy led to significant reductions of serum ALT (85%), serum AST (33.4%), liver steatosis (65.4%), inflammation (86.7%), ballooning degeneration (60%), and NAFLD activity score (86.4%), as well as gene expression markers each of fibrosis (αSMA, TGFβ, COL1A, TXNIP) by 88-92%, inflammation (TNFa, IL1β, MCP1, iNOS) by 91-97%, ER stress (DDIT3, ATF, sXBP1, HSPA5) by 45-93%, steatosis (ACC1, PLIN2) by 31-97%, and fatty acid oxidation (PPARα, PGC1α, CPT1, UCP1) by 65-86, and reduced the percent fibrosis area by 92.7% relative to vehicle (and resultantly similar to normal diet mice) (all above: P<0.05) and by amounts greater than B or C alone or additively. This study demonstrates the positive interactive effects of bromocriptine and curcumin on advanced liver fibrosis in an MCD diet model of NASH. NASH is characterized by severe hepatic fibrosis that potentiates cirrhosis and hepatocellular carcinoma. The MCD diet also potentiates severe liver fibrosis by reducing lipid secretion and antioxidant defenses, and adversely altering the gut microbiome to promote liver inflammation and damage. B, a dopamine D2 receptor agonist reduces adipose lipolysis and hepatic lipogenesis and inflammation. C improves a gut microbiome adverse to liver. C is also known to augment brain dopaminergic activity. We therefore investigated if B and C combination therapy that engages different pathological targets of NASH may provide an additive/synergistic benefit against MCD diet induced liver fibrosis. C57B6 mice were fed an MCD diet for 8 weeks to induce NASH with fibrosis then randomized to 4 treatment groups: Vehicle, B (10mg/kg), C (100mg/kg), and combination of B and C (BC) daily for 4 weeks while maintained on the diet. A group of mice on normal diet were used as normal reference control. BC therapy led to significant reductions of serum ALT (85%), serum AST (33.4%), liver steatosis (65.4%), inflammation (86.7%), ballooning degeneration (60%), and NAFLD activity score (86.4%), as well as gene expression markers each of fibrosis (αSMA, TGFβ, COL1A, TXNIP) by 88-92%, inflammation (TNFa, IL1β, MCP1, iNOS) by 91-97%, ER stress (DDIT3, ATF, sXBP1, HSPA5) by 45-93%, steatosis (ACC1, PLIN2) by 31-97%, and fatty acid oxidation (PPARα, PGC1α, CPT1, UCP1) by 65-86, and reduced the percent fibrosis area by 92.7% relative to vehicle (and resultantly similar to normal diet mice) (all above: P<0.05) and by amounts greater than B or C alone or additively. This study demonstrates the positive interactive effects of bromocriptine and curcumin on advanced liver fibrosis in an MCD diet model of NASH. Disclosure T. Tsai: Employee; Self; VeroScience LLC. A. Cincotta: Employee; Self; VeroScience LLC. |
Author | CINCOTTA, ANTHONY TSAI, TSUNG-HUANG |
Author_xml | – sequence: 1 givenname: TSUNG-HUANG surname: TSAI fullname: TSAI, TSUNG-HUANG organization: Tiverton, RI – sequence: 2 givenname: ANTHONY surname: CINCOTTA fullname: CINCOTTA, ANTHONY organization: Tiverton, RI |
BookMark | eNotkU1r3DAQhkVJoZuPU__AQC-7FDeSZUtWbxtv0wSyaUhy6M3I8phV8EquJBf6r_oTa7NlDnN5eHhn3nNy5rxDQj4y-iXnXF53LVMZq0qWPb0jK6a4ynguf56RFaUsz5hU8gM5j_GNUirmWZG_J_or3AR_9CbYMVmHsL7ZwDhMEeopmOloHazrDdy7hEGbBMnDM3aTQdh2v7Uz2MGtbYOPNsLMatj7KSLsMR2sd7Mwqw9-WMQ77K2x6BKs9_VuAzuLaaY7HMD38OidHoxfWAMvCXXyBxx1smkWrx-3L3ebS_K-10PEq__7grzefnut77KHH9_v6-1DZkTBMsz7oitNzitTiZJVHPu8bFVfIW-5LEqhK1RSVEaZVupCUC6FlkK0qJXmqPgF-XTSjsH_mjCm5s1PYU4XmzwvKq5kQdlMfT5RZr49BuybMdijDn8aRpulkWZppFl-3Dzxfw19fsk |
ContentType | Journal Article |
Copyright | Copyright American Diabetes Association Jun 1, 2019 |
Copyright_xml | – notice: Copyright American Diabetes Association Jun 1, 2019 |
DBID | AAYXX CITATION K9. NAPCQ |
DOI | 10.2337/db19-1851-P |
DatabaseName | CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium |
DatabaseTitle | CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium |
DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1939-327X |
ExternalDocumentID | 10_2337_db19_1851_P |
Genre | Conference Proceeding |
GroupedDBID | --- .55 .XZ 08P 0R~ 18M 29F 2WC 354 4.4 53G 5GY 5RE 5RS 5VS 6PF 8R4 8R5 AAQQT AAWTL AAYEP AAYOK AAYXX ABOCM ACGFO ACGOD ACPRK ADBBV AEGXH AENEX AERZD AFHIN AHMBA AIAGR AIZAD ALIPV ALMA_UNASSIGNED_HOLDINGS BAWUL BES BTFSW CITATION CS3 DIK DU5 E3Z EBS EDB EJD EMOBN EX3 F5P FRP GX1 H13 HZ~ IAO IEA IHR INH INR IOF IPO K2M KQ8 L7B M5~ O5R O5S O9- OHH OK1 OVD P2P PCD Q2X RHF RHI RPM SJN SV3 TDI TEORI TR2 VVN W8F WH7 WOQ WOW X7M YFH YHG YOC ZY1 ~KM K9. NAPCQ |
ID | FETCH-LOGICAL-c641-e2f4d5c238c865183ef25b9f8e3b37456a8e9768c9cb7a460376a766bea9a3e93 |
ISSN | 0012-1797 |
IngestDate | Thu Oct 10 19:08:00 EDT 2024 Fri Aug 23 03:43:23 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Supplement_1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c641-e2f4d5c238c865183ef25b9f8e3b37456a8e9768c9cb7a460376a766bea9a3e93 |
PQID | 2248397401 |
PQPubID | 34443 |
ParticipantIDs | proquest_journals_2248397401 crossref_primary_10_2337_db19_1851_P |
PublicationCentury | 2000 |
PublicationDate | 2019-06-01 20190601 |
PublicationDateYYYYMMDD | 2019-06-01 |
PublicationDate_xml | – month: 06 year: 2019 text: 2019-06-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | New York |
PublicationPlace_xml | – name: New York |
PublicationTitle | Diabetes (New York, N.Y.) |
PublicationYear | 2019 |
Publisher | American Diabetes Association |
Publisher_xml | – name: American Diabetes Association |
SSID | ssj0006060 |
Score | 2.3404045 |
Snippet | NASH is characterized by severe hepatic fibrosis that potentiates cirrhosis and hepatocellular carcinoma. The MCD diet also potentiates severe liver fibrosis... |
SourceID | proquest crossref |
SourceType | Aggregation Database |
SubjectTerms | Antioxidants Bromocriptine Choline Cirrhosis Curcumin Diet Dopamine D2 receptors Fatty liver Fibrosis Gene expression GRP78 protein Hepatocellular carcinoma Inflammation Interleukin 1 Intestinal microflora Lipogenesis Lipolysis Liver Liver cirrhosis Methionine Microbiomes Neurodegeneration Nitric-oxide synthase Nutrient deficiency Oxidation Steatosis Tumor necrosis factor-α |
Title | 1851-P: Bromocriptine (B) plus Curcumin (C) Interact to Reduce Advanced Fibrosis in a Mouse Methionine-Choline Deficient (MCD) Diet Model of Nonalcoholic Steatohepatitis (NASH) |
URI | https://www.proquest.com/docview/2248397401 |
Volume | 68 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FIiEuqLxEaUFz6CERMiR27Hi5OQ7FBdVUxJHCyVpvN0okiKvGvvCruPD_mNm1XSfkULhYkeVdy5nPM9-M58HYqUNGhVPcra-oqTbqQS6FY0m050rYyke9TNkWsRfNhp_m7rzT-d3KWiqL7K38ubeu5H-kiudQrlQl-w-SbTbFE_gb5YtHlDAe7yRjtIID65Kc-jFl1RkFYFjjmNz96-_l5k1Y3sjyx2qtv9fSWR0EpNJIpJ1fqXOrHstsMgHO0HvOqUcJXi_whS83-NqrYqmjtsoKl7mmpRNFjSeqbqUX4YS2naxUoUeraXYbE8PX03dXklLJ0LdfKsreLlY6zhsH06iOQlTceNIKA-8OCGoFLJJpcK5RNp3FH61oFsTNeLDQhCgCrfDiJPoSf2tHNaiQqs6-qjX1wKbWqcYYK6OcucMtxx7N29rb81so1ZNQdVg1HeyzD7ajOwxcZXhDI6JbM1h_-t-xjk3OInpLtDylxSktTi_vsfs26jedHXD-uSEA6BOayqfqEUxZKC1-17rzNhHa5gGa3CSH7FHllUBgIPaYddT6CXtwUeVdPGW_zGbvYQtn0B33gDAGNcagG_agxhcUORh8QY0vqPEFeK0AjS_4G1_Q4Au6iK4eELZAYwvyBbSxBTvYgi4hq_eMJWcfkjCyqlkflvSGA0vZi-GVK5E_St9z0cyohe1mfOErJ3NGSPKFr5A4-5LLbCSGXh_tohh5XqYEF47iznN2sM7X6gUD7gmqr1Z9wV1ytjPHy2yOTF-iZ-C62RE7rf_39Np0dEn3yPaIndQySatXfpMi30WHgoZYvrzbLsfs4S26T9hBcVOqV8hii-y1xswfj8SUXA |
link.rule.ids | 315,783,787,27936,27937 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=1851-P%3A+Bromocriptine+%28B%29+plus+Curcumin+%28C%29+Interact+to+Reduce+Advanced+Fibrosis+in+a+Mouse+Methionine-Choline+Deficient+%28MCD%29+Diet+Model+of+Nonalcoholic+Steatohepatitis+%28NASH%29&rft.jtitle=Diabetes+%28New+York%2C+N.Y.%29&rft.au=TSAI%2C+TSUNG-HUANG&rft.au=CINCOTTA%2C+ANTHONY&rft.date=2019-06-01&rft.issn=0012-1797&rft.eissn=1939-327X&rft.volume=68&rft.issue=Supplement_1&rft_id=info:doi/10.2337%2Fdb19-1851-P&rft.externalDBID=n%2Fa&rft.externalDocID=10_2337_db19_1851_P |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-1797&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-1797&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-1797&client=summon |